ROSSINI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.783
NA - Nord America 1.370
EU - Europa 825
SA - Sud America 178
OC - Oceania 27
AF - Africa 20
Totale 4.203
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.353
CN - Cina 668
SG - Singapore 568
RU - Federazione Russa 520
KR - Corea 224
HK - Hong Kong 148
BR - Brasile 139
IT - Italia 130
VN - Vietnam 61
IN - India 48
GB - Regno Unito 31
PL - Polonia 30
AU - Australia 27
FI - Finlandia 26
DE - Germania 25
ID - Indonesia 16
IE - Irlanda 14
AR - Argentina 13
MX - Messico 11
SE - Svezia 11
EC - Ecuador 10
BD - Bangladesh 9
FR - Francia 9
BJ - Benin 8
AE - Emirati Arabi Uniti 7
JO - Giordania 7
NL - Olanda 7
JP - Giappone 6
CO - Colombia 5
CZ - Repubblica Ceca 5
UA - Ucraina 5
CA - Canada 4
IQ - Iraq 4
ZA - Sudafrica 4
ES - Italia 3
PY - Paraguay 3
UZ - Uzbekistan 3
AT - Austria 2
CL - Cile 2
EG - Egitto 2
KW - Kuwait 2
LT - Lituania 2
MA - Marocco 2
PE - Perù 2
PK - Pakistan 2
TR - Turchia 2
VE - Venezuela 2
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
LK - Sri Lanka 1
LV - Lettonia 1
MU - Mauritius 1
QA - Qatar 1
SA - Arabia Saudita 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 4.203
Salva come PNG Salva come JPEG
Città #
Santa Clara 874
Singapore 443
Hefei 328
Seoul 224
Hong Kong 144
Ashburn 88
Beijing 58
Kent 35
Warsaw 29
Los Angeles 27
Melbourne 27
Buffalo 26
Bengaluru 22
London 21
Moscow 21
Mumbai 20
Ho Chi Minh City 19
Florence 18
Helsinki 18
Hanoi 15
Dublin 14
Arezzo 13
São Paulo 13
Milan 12
The Dalles 11
Cologne 10
Jakarta 10
Chandler 9
New York 9
Shanghai 9
Cotonou 8
Dallas 8
Tianjin 8
Boston 7
Brooklyn 7
Lappeenranta 6
Munich 6
Rio de Janeiro 6
Fairfield 5
Haiphong 5
Rome 5
Salvador 5
Yubileyny 5
Council Bluffs 4
Elk Grove Village 4
Frankfurt am Main 4
Modena 4
Orem 4
Podivín 4
Poplar 4
Stockholm 4
Tokyo 4
West Jordan 4
Baghdad 3
Chicago 3
Curitiba 3
Dhaka 3
Gradignan 3
Guayaquil 3
Manchester 3
Mexico City 3
Salt Lake City 3
Seattle 3
Siena 3
Altamura 2
Ann Arbor 2
Bari 2
Belo Horizonte 2
Bismarck 2
Biên Hòa 2
Bologna 2
Cabo Frio 2
Cairo 2
Calcinaia 2
Cambridge 2
Campi Bisenzio 2
Chengdu 2
Chennai 2
Columbus 2
Cotia 2
Da Nang 2
Dong Ket 2
Düsseldorf 2
Feira de Santana 2
Guarulhos 2
Houston 2
Hải Dương 2
Joinville 2
Kampong Loyang 2
Las Vegas 2
Lauterbourg 2
Lawrence 2
Lurate Caccivio 2
Madrid 2
Matelica 2
Montreal 2
Naples 2
Ninh Bình 2
Nuremberg 2
Porciúncula 2
Totale 2.793
Salva come PNG Salva come JPEG
Nome #
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 198
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 191
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation 150
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 131
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 129
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 125
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 124
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 121
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV 120
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: Lessons from the AtezoT RIBE study 119
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 118
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 117
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 115
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials 115
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial 114
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 114
EGFR Amplification in Metastatic Colorectal Cancer 113
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 112
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 109
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 108
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 105
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 103
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 103
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 101
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 101
Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm 99
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 97
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 94
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 93
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population 90
KDR genetic predictor of toxicities induced by sorafenib and regorafenib 88
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 81
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 77
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration 72
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 71
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 67
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 60
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer 57
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 57
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm? 53
Individual patient data meta-analysis of folfoxiri plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer 27
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study 16
Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS 11
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift 10
Totale 4.276
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.127
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202124 0 0 0 0 0 5 4 4 2 6 0 3
2021/20227 0 0 0 1 0 0 0 1 0 1 2 2
2022/202360 1 8 1 2 2 10 10 5 12 0 6 3
2023/2024144 1 5 4 10 4 10 9 31 2 54 9 5
2024/20252.111 75 200 100 206 658 370 77 45 77 41 108 154
2025/20261.911 282 447 514 302 338 28 0 0 0 0 0 0
Totale 4.276